



ADVANCED THERAPIES WEEK

January 17th – 20th 2023
Miami Beach Convention Center

**The destination to form
partnerships, by day, and by night.**

2023 Platinum Sponsors


charles river


DARK HORSE CONSULTING

FUJIFILM
Diosynth
biotechnologies

FUJIFILM
Value from Innovation
 IrvineScientific

 Germfree


BLOOD AND CELL
TECHNOLOGIES

 
WuXi AppTec

Contents

Introduction	3
Why Advanced Therapies Week	4
Welcome	5
Event in Numbers	6
Who Attends?	7
Speaker Spotlight	8
Agenda.....	9-20
Floorplan	21
Networking Events and Experiences - Miami Days	22
Networking Events and Experiences - Miami Nights	23
Hotel Accomodation	24
Get Involved	25
Get in Touch with our Team	26



Introduction

Advanced Therapies Week is an event like no other. With networking opportunities taking place from morning to night, we provide attendees with an outstanding experience that entails thought-provoking content, high-profile speakers, and unmissable networking events. We bring together the advanced therapies field in the most memorable way, and we guarantee you'll want to be involved.

By bringing together the breadth of the industry, we form a central hub for long-lasting partnerships to be born. Located in Miami, we'll put an end to your January blues, and leave you feeling energized and enlightened to progress further in your commercialization journey – at whichever stage you may currently be.

Whether you're looking for your next ground-breaking investment, or are in search of a deeper topic understanding, Advanced Therapies Week is for you.



Why Advanced Therapies Week?

- It's the largest, most immersive marketplace for cell and gene therapy
- Featuring **180+ tools and tech** companies who share our goal to help biotechnology companies along their commercialization journey
- **50+ tech launches** are scheduled for the event
- **Interactive demonstrations** by the key companies driving efficient R&D and commercial-scale manufacturing (including a mobile cleanroom with Germfree)
- Opportunities to **form partnerships** by day, and by night. There's something to suit everyone - from wellness breaks to our much-loved Yacht Party for a tour down Millionaire's Row
- We provide the **right mix of technical and strategic content**, sharing ideas for actionable strategies, to help you build and bolster your commercialization plan
- It's purposefully positioned to **kick-start the year** to build sales pipelines, identify new partners, and spark ideas to inspire the field for the year ahead



Welcome

Embrace the #PowerOfPartnerships

It's a great pleasure to welcome you to learn more about the 18th annual Advanced Therapies Week. I am very excited to confirm this will be in one of my favourite destinations, Miami! It is important for us to celebrate the progression the industry has seen over these past couple of years, while also discussing solutions to help us keep moving forward together. #PowerOfPartnerships.

This year we have a lot more in store for you, including an awards dinner to celebrate all the progress and success we've seen in the advanced therapies field. You will also be pleased to hear that the Yacht Party is back with a bigger boat and a new route around Millionaire's Row. If you are more of a morning person rather than a night owl, then our sunrise beach yoga and fun run could be the best option for you; but don't worry if not, as Advanced Therapies Week is not far from a 24-hour experience, and the fun doesn't stop when the sun goes down.

Here are a few things I am looking forward to:

- **Six streamlined content tracks** set up to help biotech progress along their commercialization journey, with two new tracks focused on clinical innovation and patient centric development
- The **largest and most immersive marketplace** for cell and gene therapy
- The **Phacilitate Food Fest**- think pizza trucks and comfy seating
- The **Exhibition Opening Party** - don't worry the basketball hoop is back!

I hope to see you there!




Kim Barnes
Executive Vice
President

Event in Numbers



Who Attends?



Speaker Spotlight

Take a look at just a few of the experts joining our speaker panel this year...



Allyson Berent,
Co-director,
**Foundation for Angelman
Syndrome Therapeutics**
Co-Founder and Chief
Scientific Officer,
GeneTx



Joanne Brewer,
Chief Scientific Officer,
AdaptImmune



Courtney Horvarth,
Global Head of strategy,
Planning and Operations,
translational Medicine
Novartis



Kimberly Goodspeed,
Associate Professor,
University of Texas



Arthur Stril,
Chief Business Officer,
Cellectis



Wilson Bryan,
Director for Policy,
**Office of Tissues and
Advanced Therapies**
FDA



Dr. Gwen Nichols
Chief Medical Officer,
**The Leukaemia &
Lymphoma Society**



Boro Droplic,
Executive Director and
Founder,
Caring Cross



Gwen Binder,
President and Head of
Research,
Cabaletta Bio



Anne Rowzee
Associate Director of
Tissues and Advanced
Therapies,
FDA

Check out the speaker list

Agenda

Pre-Day - January 17th 2023

04:00pm–05:30pm	Superplenary: Opening Inspirational Fireside Chats
	Chair Introduction: Anthony Davies, Founder & Chief Executive Officer, Dark Horse Consulting Group
	Fireside Chat #1: Gwen Nichols, Chief Medical Officer, Leukemia & Lymphoma Society
	Fireside Chat #2: Michael E. Meyers, Chief Executive Officer, Cell BT
	Fireside Chat #2: Participant Details Coming Soon
	Fireside Chat #2: Participant Details Coming Soon
	Discussion
05:30pm–07:00pm	EXHIBITION OPENING PARTY

Agenda

Day 1 - January 18th 2023

06:30am	KICK-START YOUR DAY WITH A 5KM MID-BEACH RUN FOLLOWED BY SMOOTHIES		
08:00am–09:00am	Morning Briefing 1 Hosted by: Thermo Fisher Scientific		Morning Briefing 2
09:00am–10:30am	Opening Plenary: Enabling Access Through Innovation - Cell and Gene Therapy in 2023 and Beyond		
	Chair Introduction: Jörg Shneider, Associate Principal Consultant, Biopharma Excellence		
	Presentation: Top 10 Events of 2022: Susan Nichols, Chief Business Officer, ViroCell Biologics		
	Presentation: TBC: Dominic Clarke, Chief Technical Officer, Cell & Gene Therapy, Discovery Life Sciences		
	Presentation: Update on the Research Landscape for Cell and Gene Therapies: David Barrett, Chief Executive Officer, ASGCT		
	Panel Discussion: How Are We Enabling Innovation for Cell and Gene Therapies?: TBC		
10:30am–11:00am	Morning Refreshment Break - Partnering - Tech Demos		

11:00am–12:30pm	Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations	New and Enabling Tech
	Allogeneic Cell Therapies: How Do We Get Off-the-Shelf Therapies Off the Ground? Chair Introduction: Joanne Brewer, Chief Scientific Officer, AdaptImmune Presentation: Senior Representative, ATARA Biotherapeutics Presentation: Senior Representative, Be The Match Presentation: Olivier Negre, Chief Scientific Officer, Smart-Immune Presentation: Dan Kemp, Chief Executive Officer, Wugen Presentation: Senior Representative, Tevogen	What is the Public and Patient Perception of Cellular Therapies? Chair Introduction: Ryan Leahy, Vice President of Research, Phacilitate Presentation: Courtney Horvarth, Global Head of Strategy, Planning and Operations, Novartis Presentation: Senior Representative, Vertex Pharmaceuticals Presentation: Senior Representative, Alliance for Regenerative Medicine Presentation: Teonna Woolford, Chief Executive Officer, Sickle Cell RED Panel Discussion: Session Participants	Cell Therapy Commercial Success, Overcoming Pitfalls and What We Have Learned from 2021 Chair Introduction: Peter Olagunju, Chief Technical Officer, TCR2 Therapeutics Presentation: Arthur Stril, Chief Business Officer, Cellectis Presentation: Senior Representative, Center for Breakthrough Medicines Presentation: Cintia Piccina, Chief Commercial Officer, AdaptImmune Presentation: Scott Jones, Chief Scientific Officer, BioBridge Global Panel Discussion: Session Participants	Accelerating Clinical Manufacturing: Working with New, Promising Therapeutics Chair Introduction: Chairperson TBC Presentation: Marc Wolfgang, Vice President of Technical Development, BioNTech Presentation: Senior Representative, Catalent Presentation: Riccardo Baptista, Chief Technical Officer, Alder Therapeutics Presentation: TBC Panel Discussion: Session Participants	What Does a Global Supply Chain Look Like for CGT? Defining End-to-End Logistics Chair Introduction: Senior Representative, Exacis Therapeutics Presentation: Senior Representative, ATHERSYS Presentation: Senior Representative, QuickSTAT Presentation: Benoit Bossuge, Head of Strategic Sourcing, CRISPR Therapeutics Presentation: Senior Representative, WorldCourier Presentation: Session Participants	The Future of Viral Vectors Chair Introduction: Nicole Paulk, Associate Professor, University of California, San Francisco Presentation: Will Junker, Head of Vector Manufacturing Quality, Kite Pharma Presentation: James Miskin, Chief Technical Officer, Oxford Biomedica Presentation: TBC Panel Discussion: Session Participants
12:30–1:30pm	Lunch Briefing 1 Hosted by: Terumo BCT, Inc.		Lunch Break - Partnering		Lunch Briefing 2 Hosted by: Sony Biotechnology Inc.	

01:30pm–03:00pm	Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations	New and Enabling Tech
	Gene Therapies: Advancing Curative Medicines for Rare and Genetic Disease Chair Introduction: John Rasko, Professor, University of Sydney Presentation: Allyson Berent, Chief Science Officer, Foundation for Angelman Syndrome Therapeutics (FAST) Presentation: TBC Presentation: Senior Representative, bluebird bio Presentation: Essra Ridha, Chief Medical Officer, AVROBIO Panel Discussion: Session Participants	Implementing Novel Development Strategies for Clinical Trials Chair Introduction: Samik Basu, Chief Scientific Officer, Cabaletta Bio Presentation: Kimberly Goodspeed, Assistant Professor, UT Southwestern Medical Center Presentation: Senior Representative, Syneos Presentation: Michael Forstner, Head of Patient Safety, Biogen Presentation: TBC Panel Discussion: Session Participants	Patient-Centric Development: Keeping the Patient at the Heart of Commercialization for New Medicines Chair Introduction: Tom Whitehead, Founder, Emily Whitehead Foundation Presentation: Senior Representative, bluebird bio Presentation: TBC Presentation: Farah Speer, Senior Vice President, AviadoBio Presentation: Senior Representative, Taysha Gene Therapies Panel Discussion: Session Participants	Getting to Commercial Manufacturing: Producing Therapies for Patient Need Chair Introduction: Ohad Karnieli, Chief Executive Officer, ADVA Biotechnology Presentation: Don Healey, Chief Technology Officer, Adicet Bio Presentation: Senior Representative, Cytiva Presentation: Lesley Chan, Director of Cellular Process Development, bluebird bio Presentation: J. Kelly Ganjei, President and Chief Executive Officer, Amplify Bio Panel Discussion: Session Participants	Collection and Apheresis: Specialist Handling of Patient Material Chair Introduction: Yossi Schwartz, Professor, Icahn School of Medicine at Mt. Sinais Presentation: Jean Stanton, Director, Commercial Apheresis Operations, Janssen Presentation: Senior Representative, Terumo Blood and Cell Technologies Presentation: TBC Presentation: Senior Representative, Cryoport Presentation: Session Participants	How Are We Developing Necessary Manufacturing Capacity for Chair Introduction: Jeff Masten, Chief Operating Officer, Theragent Presentation: Senior Representative, ATARA Biotherapeutics Presentation: TBC Presentation: Steven Doares, Senior Vice President and Site Head, US Manufacturing, Cellectis Panel Discussion: Senior Representative, MERIT Presentation: Session Participants
3:00–3:30pm	Afternoon Refreshment Break - Partnering - Tech Demos					

3:30–5:00pm	Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations	New and Enabling Tech
	Cell and Gene Therapy for Autoimmune Disorders Chair Introduction: Arun Das, Chief Business Officer, Cabaletta Bio Presentation: Karen Walker, Chief Technical Officer, Kyverna Therapeutics Presentation: TBC Presentation: TBC Presentation: Gwen Binder, President Science and Technology, Cabaletta Bio Panel Discussion: Session Participants	Working With Qualified Treatment Centers for Best Patient Outcomes Chair Introduction: TBC Presentation: Courtney Wells, Senior Vice President, Talaris Therapeutics Presentation: TBC Presentation: Ronit Slotsky, Director, Cell Therapy Manufacturing Facility, Hackensack Medical Center Presentation: TBC Panel Discussion: Session Participants	Paying for Cures: Creative Payment, Reimbursement and Market Access Models - Defining Value in the CGT Space Chair Introduction: Senior Representative, MIT NEWDIGS Presentation: Kristin Viswanathan Wolff, Vice President, Market Access, bluebird bio Presentation: TBC Presentation: Andrew Olaye, Executive Director, Market Access, Orchard Therapeutics Presentation: Tay Salimullah, Vice President, Head of Global Value and Access, Novartis Gene Therapiess Panel Discussion: Session Participants	Building Robust Manufacturing Processes for Gene Therapies Chair Introduction: Vishal Agarwal, Vice President, CMC and Process Development, Eikonoklastes Therapeutics Presentation: Alex Bloom, Senior Vice President, Technical Operations, AviadoBio Presentation: Senior Representative, Forge Biologics Presentation: Scott Bertch, Executive Director, Clinical Site Head, Tenaya Therapeutics Presentation: Senior Representative, Charles River Laboratories Panel Discussion: Session Participants	Think Locally, Source Globally: Are Your Products Region-Fixed or Trans-Continental? Chair Introduction: Troels Jordansen, Chief Executive Officer, GlycoStem Presentation: Beth Gardner, Senior Director, Patient Supply, Beam Therapeutics Presentation: Senior Representative, FujiFilm Irvine Scientific Presentation: Jeff Liter, Chief Executive Officer, Luminary Therapeutics Presentation: TBC Presentation: Lisa McClain-Moss, Vice President, Manufacturing, Longeveron	Disruptive Automation Technologies: Closed Systems and Mechanizing the Workflow Chair Introduction: Lior Raviv, Chief Technical Officer, Pluri Presentation: ohn Campbell, Director, Tissues, Cells and Advanced Therapeutics, SNBTS Presentation: Sean Buckley, Consultant, Emerson Automation Experts Presentation: TBC Panel Discussion: Senior Representative, Sony Biotechnology Presentation: Session Participants
12:30–1:30pm	Evening Briefing 1 Hosted by: Cytiva				Evening Briefing 2	

6:30–9:30pm

YACHT PARTY

Agenda

Day 2 - January 19th 2023

07:00am–08:00am

SUNRISE YOGA ON THE BEACH AND WELLNESS HOUR

08:30am–09:30am

Morning Briefing 1
Hosted by Invetech

Morning Briefing 2
Hosted by FUJIFILM Irvine Scientific

9:30–10:30am

Roundtable Discussions

10:30am–11:00am

Roundtable 1:
Amy House, Integration and Transition
Lead, Gyroscope Therapeutics

Roundtable 2:
Moderator TBC

Roundtable 3:
Eric Hacherl, Vice President, Head of
Manufacturing, Spark Therapeutics

Roundtable 4:
Moderator TBC

Roundtable 5:
Matt Li, Senior Director, Tome Bio

Roundtable:
Moderator TBC

Roundtable 9:
Arnaud Deladeriere, Director, Process
Development, Triumvira Immunologics

Roundtable 8:
Moderator TBC

10:30–11:00am

Morning Refreshment Break - Partnering - Tech Demos

11:00am–12:30pm

Modalities and Indications

Patient and Clinical Considerations

Commercializing the Therapies of the Future

Manufacturing Advanced Therapies

Supply Chain & Technical Operations

New and Enabling Tech

CAR-T Therapies: 10 Years On and the Future of CAR-T

Chair Introduction:
Steve Kanner, Chief Scientific Officer, Caribou Biosciences

Presentation:
TBC

Presentation:
Senior Representative, Adaptive Biotechnologies

Presentation:
Dan Shelly, Vice President, Prescient Therapeutics

Presentation:
TBC

Panel Discussion:
Session Participants & Jennifer Chow, Chief Executive Officer, Chimeric Therapeutics

Working With Patient Advocacy Organizations to Inform Development

Chair Introduction:
Sharon Hesterlee, Chief Research Officer, Muscular Dystrophy Association USA

Presentation:
Tom Whitehead, Founder, Emily Whitehead Foundation

Presentation:
TBC

Presentation:
Gwen Nichols, Chief Medical Officer, Leukemia and Lymphoma Society

Presentation:
Anne Rowzee, Associate Director

Panel Discussion:
Session Participants

Commercializing Gene Therapies: Building Your Strategy From Translation Through to Commercial

Chair Introduction:
Serene Forte, Senior Vice President, Head of Genetic Medicine, RELIEF Therapeutics

Presentation:
Emily Chee, General Manager, Americas, Novartis Gene Therapies

Presentation:
Senior Representative, AmerisourceBergen

Presentation:
Frederic Chereau, Chief Executive Officer, LogicBio

Presentation:
Senior Representative, FujiFilm Diosynth

Panel Discussion:
Session Participants & Sean McAuliffe, Chief Commercial Officer, Taysha Gene Therapies

Building Better Quality Products: Quality Control and Assurance

Chair Introduction:
TBC

Presentation:
Azadeh Golipour, Chief Technical Officer, AVROBIO

Presentation:
Senior Representative, BioMerieux

Presentation:
TBC

Presentation:
Senior Representative, Accelix

Panel Discussion:
Session Participants & Eric Hacherl, Vice President, Head of Manufacturing, Spark Therapeutics

Enhancing Technical Knowledge in CGT: Training Skilled Personnel for the Technical Workforce of the Future

Chair Introduction:
Senior Representative, Canadian Advanced Therapies Training Institute (CATTI)

Presentation:
John Balachunas, Workforce Director, NIIMBL

Presentation:
Senior Representative, CAI

Presentation:
Jenny Ligon, Associate Director, Workforce Development, National Center for Therapeutics Manufacturing, Texas AM

Presentation:
Senior Representative, Elevate Bio

Presentation:
Session Participants

Innovative Delivery Technology for Gene and Cell Therapy

Chair Introduction:
Vincent Ling, Head of Search and Evaluation for Drug Delivery Technologies, Takeda

Presentation:
Pierre Boulas, Head of Medical Devices and Packaging Development, Biogen

Presentation:
Senior Representative, Avectas

Presentation:
TBC

Panel Discussion:
TBC

Presentation:
Session Participants

12:30–1:30pm	Lunch Briefing 1 Hosted by: Miltenyi Biotec		Lunch Break Partnering Women in Advanced Therapies Roundtable Discussion GermFree Mobile Cleanroom Experience		Lunch Briefing 2 Hosted by: Resilience	
1:30–3:00pm	Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations	New and Enabling Tech
	Gene Therapies Entering the Mainstream - What Are the Next Gene Therapy Treatments? Chair Introduction: Nicole Paulk, Associate Professor, University of California, San Francisco Presentation: Senior Representative, Rocket Pharmaceuticals Presentation: TBC Presentation: Faraz Ali, Chief Executive Officer, Tenaya Therapeutics Presentation: Jenny Holt, Senior Vice President, Program and Portfolio Management, Ray Therapeutics Panel Discussion: Session Participants	Decentralizing Advanced Therapies: Are We Moving Closer to Bedside Therapeutics? Chair Introduction: Miguel Forte, President Elect, International Society for Cell & Gene Therapy Presentation: Boro Dropulic, Executive Director, Caring Cross Presentation: Ohad Karnieli, Chief Executive Officer, ADVA Biotechnology Presentation: TBC Presentation: TBC Panel Discussion: Session Participants	People Behind the Cures: the CGT Workforce - Recruitment, Opportunity and Diversity Chair Introduction: Angela Justice, Chief People Officer, TCR2 Therapeutics Presentation: TBC Presentation: TBC Presentation: Scott Gottesman, Vice President, Human Resources, AVROBIO Presentation: TBC Panel Discussion: Session Participants & John Balchunas, Workforce Director, NIIMBL	Is cGMP Enough? Operational Excellence for Advanced Medicines Chair Introduction: Frank Thielmann, Head Lean - Global Operational Excellence, Takeda Presentation: David Sourdive, Vice President of Corporate Development and Co-Founder, Collectis Presentation: TBC Presentation: Irina Kadiyala, Senior Director, Vertex Pharmaceuticals Presentation: TBC Panel Discussion: Session Participants	Storage and Preservation to Maintain High-Quality Raw Materials and Therapeutics Chair Introduction: TBC Presentation: Senior Representative, Kyverna Therapeutics Presentation: TBC Presentation: Troels Jordansen, Chief Executive Officer, GlycoStem Therapeutics Presentation: Senior Representative, Sartorius Stedim Biotech Presentation: Session Participants	Digital Futures for CGT: Digitalization and Data Management to Enhance Development Chair Introduction: Fabio Fachin, Head, Cell Therapy Process Development and Automation/Digital, Takeda Presentation: TBC Presentation: TBC Panel Discussion: Meghan Verschoor, Associate Director, Data Science in Clinical Turnstone Biologics Presentation: TBC Presentation: Session Participants

3:00–3:30pm

Afternoon Refreshment Break - Partnering - Tech Demos

3:30–5:00pm

Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations	New and Enabling Tech
Autologous Cell Therapies: New Developments in Cell-Based Immunotherapy Chair Introduction: Bruce Levine, Professor, University of Pennsylvania Presentation: Joanne Brewer, Chief Scientific Officer, AdaptImmune Presentation: TBC Presentation: Frank Borriello, Chief Executive Officer, Alloplex Biotherapeutics Presentation: Jason Litten, Chief Medical Officer, Chimeric Therapeutics Panel Discussion: Session Participants	Reaching More Patients with CGT: Screening, Genomics, Databases and Patient Diversity Chair Introduction: Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics Presentation: Emily McGinnis, Chief Patient Officer, Taysha Gene Therapies Presentation: TBC Presentation: Ana Rosa Sáez Ibáñez, Research Analyst, Cancer Research Institute Presentation: TBC Panel Discussion: Session Participants & Kevin Ramdas, Director, Medical Affairs & Clinical Operations, Longeveron	Workshop: Investment in CGT - Securing Funding for your Biotech Venture Chair Introduction: Sven Kili, Chief Executive Officer, Antion Biosciences Presentation: Jennifer Chow, Chief Executive Officer, Chimeric Therapeutics Presentation: TBC Presentation: TBC Presentation: TBC Panel Discussion: Session Participants & Miguel Forte, President-Elect, International Society for Cell & Gene Therapy	CRL Session Session Details Coming Soon!	Supply and Demand: Plasmid-Mediated Gene Therapy Chair Introduction: TBC Presentation: Fred Chereau, Chief Executive Officer, LogicBio Therapeutics Presentation: Emma Bjorgum, Vice President, Client Services, DNA, Aldevron Presentation: TBC Presentation: Senior Representative, Polyplus Transfection Presentation: Session Participants	Editing the Future: Gene Editing Tools and Technology Chair Introduction: Vincent Ling, Head of Search and Evaluation for Drug Delivery Technologies, Takeda Presentation: Pierre Boulas, Head of Medical Devices and Packaging Development, Biogen Presentation: Senior Representative, Avectas Presentation: TBC Panel Discussion: TBC Presentation: Session Participants

08:30am–09:30am	Evening Briefing 1 Be The Match BioTherapies		Evening Briefing 2
6:30–11:30pm	ADVANCED THERAPIES AWARDS DINNER		

Agenda


Day 3 - January 20th 2023

08:00am–09:00am	Morning Briefing 1 Hosted by Sartorius/Cellgenix		Morning Briefing 2		
09:00–10:30am	Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations
	Cell and Gene Therapy for Neurological Indications Chair Introduction: TBC	Disruptive and Novel Therapeutics for Oncology Indications Chair Introduction: Samik Upadhaya, Assistant Director of Scientific Affairs, Cancer Research Institute	Implementing and Integrating Disruptive Technologies for Commercial Benefit Chair Introduction: Tom Bollenbach, Chief Technology Officer, Advanced Regenerative Manufacturing Institute (ARMI)	Building Better Cell Therapy Processes Chair Introduction: Bruce Levine, Professor, University of Pennsylvania	Tracking Medicines: Digitizing and Orchestration of the Supply Chain Chair Introduction: TBC

09:00–10:30am	Modalities and Indications	Patient and Clinical Considerations	Commercializing the Therapies of the Future	Manufacturing Advanced Therapies	Supply Chain & Technical Operations
	Cell and Gene Therapy for Neurological Indications Presentation: Senior Representative, Aspen Neuroscience Presentation: TBC Presentation: Lisa Deschamps, Chief Executive Officer, AviadoBio Presentation: TBC Panel Discussion: Session Participants	Disruptive and Novel Therapeutics for Oncology Indications Presentation: Jeff Liter, Chief Executive Officer, Luminary Therapeutics Presentation: TBC Presentation: Troels Jordansen, Chief Executive Officer, GlycoStem Therapeutics Presentation: Allen Feng, Chief Scientific Officer, HebeCell Panel Discussion: Session Participants	Implementing and Integrating Disruptive Technologies for Commercial Benefit Presentation: Ryan Crisman, Co-Founder and Chief Technical Officer, Umoja Pharma Presentation: TBC Presentation: Sven Kili, Chief Executive Officer, Antion Biosciences Presentation: TBC Panel Discussion: Session Participants	Building Better Cell Therapy Processes Presentation: Lior Raviv, Chief Technical Officer, Pluri Presentation: TBC Presentation: Senior Representative, Triumvira Immunologics Presentation: TBC Panel Discussion: Rebecca Lim, Senior Vice President, Prescient Therapeutics	Tracking Medicines: Digitizing and Orchestration of the Supply Chain Session Details Coming Soon!
10:30–11:00am	Brunch Refreshment Break - Partnering				

11:00am–12:30pm	Modalities and Indications Tissue and Stem Cell Therapeutics: Breakthroughs for Regenerative Medicine Chair Introduction: John Rasko, Professor, University of Sydney Presentation: Chris Min, Chief Executive Officer, Longeveron Presentation: TBC Presentation: Dave Lennon, Chief Executive Officer, Satellite Bio Presentation: Jaeseung Lim, Chief Executive Officer and Chief Scientific Officer, Cellatoz Therapeutics Panel Discussion: Session Participants	Patient and Clinical Considerations How Do We Best Serve Small Patient and Rare Populations? Chair Introduction: TBC Presentation: Wilson Bryan, Director, Office of Tissues and Advanced Therapeutics, FDA Presentation: Brad Carlin, Senior Advisor, Statistics and Data Science, PharmaLex - US Presentation: Allyson Berent, Chief Science Officer, Foundation for Angelman Syndrome Therapeutics (FAST) Presentation: Sharon Hesterlee, Chief Research Officer, Muscular Dystrophy Association USA Panel Discussion: Session Participants	Commercializing the Therapies of the Future Technology Investment for Advanced Therapies: Investing in the Future Session Details Coming Soon!	Manufacturing Advanced Therapies Scaling Up and Out - Drastically Upsizing or Upscaling Your Cell and Gene Therapies Session Details Coming Soon!	Supply Chain & Technical Operations The Supply Chain of the Future: What Will CGT Supply Chains HAVE to Look Like in the Future? Chair Introduction: Kristy Shipulski, Vice President, Supply Chain Management, Vertex Pharmaceuticals Presentation: Tiffany Clement, Cell Therapies Core Inventory Management, Moffitt Cancer Center Presentation: TBC Presentation: Shreenal Patel, Executive Vice President, Patient Supply Operations and Quality, Achilles Therapeutics Presentation: TBC Panel Discussion: Session Participants
12:30 pm	Close of Event				

Floorplan



Networking Events and Experiences



Fun Run

🕒 Wednesday January 18th, 6.30am

Start your week in Miami strong with a **5k run along Miami beach** with the Phacilitate Team!

Sprint or take your time, this run is your opportunity to **have fun and network** with fellow active attendees and colleagues. Just bring yourselves and your running gear!

Yoga and Wellness Hour

🕒 Thursday January 19th, 7.00am

A healthy **balance between wellness and work** is needed to build the best partnerships and this is a priority at Advanced Therapies Week.

We invite you to join us for an **hour of early-morning yoga** on the Miami shore. Novice or avid enthusiast, anyone is welcome to join us and our instructor for a moment of relaxation and stress relief.



MIAMI *Nights*

Proudly
sponsored by



Exhibition Opening Party

🕒 Tuesday January 17th, 5.30pm

Is it a surprise **Advanced Therapies Week is opening with a party?** Themed zones, cocktails and ice-breakers will help us celebrate the tools and tech which are helping us get one-step closer to commercializing advanced therapies.

Join us to kick-off the conference in style!

Yacht Party

🕒 Wednesday January 18th, 6.30pm

This year we are heading back on a **yacht party trip down Millionaire's Row**. This is the perfect opportunity to take in the Miami coastline and lifestyle whilst you network the night away!

To book your place, you can either add a ticket into your basket at checkout for registration, or if you have already booked, you can follow the link found in your registration confirmation email.

ADVANCED THERAPIES AWARDS

🕒 Thursday January 19th, 6.30pm

Introducing the first edition of the **Advanced Therapies Awards** – an awards dinner to celebrate and recognize progress within the advanced therapies field. The black-tie gala dinner will be hosted by a celebrity guest, and is a great opportunity to network and celebrate the recent success seen in the industry with your peers.

Check out the website 

Hotel Accommodation

This year we have negotiated discounted rooms in nearby hotels ready for you to book when you join us at Advanced Therapies Week.

To book your room, simply follow the link in your registration email.

Fontainebleau Miami Beach

4441 Collins Ave, Miami Beach, FL 33140.



The Confidante Miami Beach

4041 Collins Ave, Miami Beach, FL 33140.



Secure your place today



Whether as a sponsor, an exhibitor, or just an attendee, you won't want to miss out on the destination to make deals in January.

	Early Bird (ends Dec 2nd)	Standard (ends Jan 17th)	On-Site (from Jan 17th)
Full Access: Academic / Government / Regulator / NFP/ Blood Bank/ Clinician/ Patient Advocate	\$940	\$1,045	\$1,570
Full Access: Biotech / Pharma	\$2,300	\$2,600	\$2,800
Full Access: Tools/Tech and Service Provider	\$3,700	\$3,700	\$4,195
Full Access: Start-Up Technology Provider (Companies with 10 or less people, been a company for 2 years or less)	\$940	\$1,045	\$1,570
Full Access: Investor (Endowment funds / Family office/ UHNWI / Private Equity and VCs only)	FREE	FREE	FREE
Full Access: Financier	\$3,700	\$3,700	\$4,195
Partnering Pass	\$1,000	\$1,000	\$1,500
Visitor Pass (exhibition only)	\$570	\$570	\$995

Get Involved

Bringing your team?

Get 15% off your ticket for bookings of 4 or more, and 25% off for bookings of 8 or more. Reach out to our team today to find out more.

Get in Touch with our Team



Nana Agyekum
Commercial Manager
07931886165 | +1 2812495653
Nana.agyekum@phacilitate.com



Natasha Fuller
Sales Executive
+44 (0)2073848204
Natasha.fuller@phacilitate.com



Cameron Binns
Sales Executive
+44 (0)2073847823
Cameron.binns@phacilitate.com

Want to place your brand front of mind at Advanced Therapies Week? We have limited sponsorship opportunities remaining.

Get in touch with our sponsorship team:



David Green
Vice President - Commercial Operations
+44 (0)2073848239
david.green@phacilitate.com